Last Price
14.80
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Market Cap
741 Million
Shares Outstanding
50 Million
Avg Volume
82,519
Avg Price (50 Days)
14.66
Avg Price (200 Days)
15.07
PE Ratio
21.14
EPS
0.70
Earnings Announcement
20-Feb-2025
Previous Close
14.98
Open
14.97
Day's Range
14.74 - 14.97
Year Range
12.96 - 18.2
Trading Volume
61,207
1 Day Change
-1.20%
5 Day Change
-2.12%
1 Month Change
5.34%
3 Month Change
-2.31%
6 Month Change
7.48%
Ytd Change
-8.98%
1 Year Change
-5.37%
3 Year Change
-63.68%
5 Year Change
-41.36%
10 Year Change
211.58%
Max Change
383.66%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Heavenly PUNTER Lynas Boleh
Potential 20 baggers
2019-06-11 14:49